#abbvie

The post Boom Times For Autoimmune Disease Therapies appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more. To get it in your inbox, subscribe here. AbbVie’s Skyrizi is on track to become the world’s second-highest selling drug, according to pharma consultants Evaluate. The Associated Press AbbVie’s Skyrizi, an injectable drug for autoimmune diseases that include psoriasis and Crohn’s disease, is expected to surpass $33 billion in revenue in 2032, making it the world’s second-biggest selling drug, according to a recent report from pharma data and consulting firm Evaluate. That puts it smack between Eli Lilly’s GLP-1 blockbusters, Mounjaro (for diabetes) and Zepbound (for weight loss). “Only autoimmune disease drugs come close to rivaling Lilly’s anti-obesity blockbusters given their potential to treat dozens of conditions driven by s

The post Buy these quality, low-stress stocks for the summer, says Jefferies appeared on BitcoinEthereumNews.com. AbbVie logo on modern glass office building with metal columns, South San Francisco, California, Oct. 16, 2025. Smith Collection | Gado | Archive Photos | Getty Images Jefferies recommends owning quality, low-stress stocks to ride out the summer as markets become more volatile amid increased concerns tied to investment in artificial intelligence. AI-related questions range from potential overcapacity, the profits that will result from hyperscalers investing an estimated $700 billion in capital spending and rising costs for tokens, the fees paid to AI models, according to a note from Desh Peramunetilleke, head of quantitative strategy at Jefferies.  As evidence of the popularity of all things AI, the S&P 500 momentum index has outperformed the broader stock market by more than 70% since 2024, close to levels seen during the dot-com run of the 1990s. Before the outbreak of wa